-
TCRX Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
TScan Therapeutics (TCRX)
Company Profile
Quarter (USD) | Sep 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 138.15 mm | 138.15 mm | 138.15 mm | 138.15 mm | 138.15 mm | |
Cash burn (monthly) | 2.47 mm | 6.31 mm | 10.87 mm | 9.18 mm | 3.75 mm | |
Cash used (since last report) | 6.91 mm | 17.68 mm | 30.46 mm | 25.70 mm | 10.51 mm | |
Cash remaining | 131.24 mm | 120.47 mm | 107.69 mm | 112.45 mm | 127.64 mm | |
Runway (months of cash) | 53.2 | 19.1 | 9.9 | 12.3 | 34.0 |
13F holders | Current |
---|---|
Total holders | 49 |
Opened positions | 29 |
Closed positions | 39 |
Increased positions | 5 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 152.62 bn |
Total shares | 39.82 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Lynx1 Capital Management | 5.22 mm | $30.56 bn |
EcoR1 Capital | 5.00 mm | $29.25 bn |
Biotechnology Value Fund L P | 4.41 mm | $14.08 mm |
Adage Capital Partners GP, L.L.C. | 4.40 mm | $25.74 bn |
BVF | 2.99 mm | $17.49 bn |
Baker Bros. Advisors | 2.78 mm | $16.29 bn |
Cormorant Asset Management | 2.50 mm | $2.45 mm |
K2 HealthVentures Equity Trust | 2.10 mm | $6.93 mm |
Longwood Fund IV | 1.28 mm | $5.76 mm |
Deer IX & Co. | 1.25 mm | $0.00 |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Dec 24 | Lynx1 Capital Management | Common Stock | Buy | Acquire P | Yes | No | 2.9014 | 100,000 | 290.14 k | 5,357,347 |
12 Dec 24 | Lynx1 Capital Management | Common stock, $0.0001 par value per share ("Common Stock") | Buy | Acquire P | Yes | No | 3.0072 | 31,800 | 95.63 k | 5,257,347 |
15 Nov 24 | Lynx1 Capital Management | Common stock, $0.0001 par value per share | Buy | Acquire P | Yes | No | 4.3442 | 947 | 4.11 k | 5,225,547 |
23 Sep 24 | Barbara Klencke | Voting Common Stock | Buy | Acquire P | No | No | 5.29 | 5,000 | 26.45 k | 45,000 |
26 Aug 24 | Barbara Klencke | Voting Common Stock | Buy | Acquire P | No | No | 5.53 | 5,000 | 27.65 k | 40,000 |
23 Aug 24 | Zoran Zdraveski | Voting Common Stock | Sell | Dispose S | No | No | 5.7814 | 164,686 | 952.12 k | 4,716 |
23 Aug 24 | Zoran Zdraveski | Voting Common Stock | Option exercise | Acquire M | No | No | 2.49 | 64,166 | 159.77 k | 169,402 |
23 Aug 24 | Zoran Zdraveski | Voting Common Stock | Option exercise | Acquire M | No | No | 1.81 | 13,125 | 23.76 k | 105,236 |
23 Aug 24 | Zoran Zdraveski | Voting Common Stock | Option exercise | Acquire M | No | No | 3.27 | 25,000 | 81.75 k | 92,111 |
23 Aug 24 | Zoran Zdraveski | Voting Common Stock | Option exercise | Acquire M | No | No | 4.85 | 54,895 | 266.24 k | 67,111 |